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Introduction: The 2017 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting,
“Beyond the Androgen Receptor II: New Approaches to Understanding and Treating
Metastatic Prostate Cancer,” was held in Carlsbad, California from June 14-17, 2017.
Methods:TheCHPCA is an annual scientific conference hosted by the ProstateCancer
Foundation (PCF) that is uniquely designed to produce extensive and constructive
discussions on the most urgent and impactful topics concerning research into the
biology and treatment of metastatic prostate cancer. The 2017 CHPCA Meeting was
the 5th meeting in this annual series and was attended by 71 investigators focused on
prostate cancer and a variety of other fields including breast and ovarian cancer.
Results: The discussions at the meeting were concentrated on topics areas including:
mechanisms and therapeutic approaches formolecular subclasses of castrate resistant
prostate cancer (CRPC), the epigenetic landscape of prostate cancer, the role of DNA
repair gene mutations, advancing the use of germline genetics in clinical practice,
radionuclides for imaging and therapy, advances in molecular imaging, and therapeutic
strategies for successful use of immunotherapy in advanced prostate cancer.
Discussion: This article reviews the presentations and discussions from the 2017
CHPCAMeeting in order to disseminate this knowledge and accelerate new biological
understandings and advances in the treatment of patients with metastatic prostate
cancer.
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1 | INTRODUCTION
The Prostate Cancer Foundation (PCF) has a legacy of driving new
innovative solutions that have reduced death and suffering from
prostate cancer through funding critical research, recruiting human
capital, supporting young investigators, facilitating global knowledge
exchange, driving new collaborations, influencing policy, and conven-
ing scientific conferences.
The Coffey-Holden Prostate Cancer Academy (CHPCA)Meeting is
an annual conference convened by PCF that gathers ∼75 investigators
to discuss themost critical avenues of research that necessitate study in
order to accelerate improved treatments for men with advanced
prostate cancer.1–4 The CHPCA Meeting is uniquely structured into
short talks followed by long discussions for the purpose of generating a
“think tank” atmosphere that stimulates brainstorming and the
development of strategic new ideas, projects, and collaborations in
most needed areas of research. A second goal of this conference is to
promote the development of early career investigators. Young
investigators comprise the meeting organizing committee as well as
roughly half of meeting attendees. This conference is modeled after the
NCI's Prouts NeckMeetings on Prostate Cancer, which took place from
1985 through 2007.5 TheCHPCAMeeting has been convened annually
byPCFsince2013, and is named for two individualswhomadehugeand
invaluable contributions toward prostate cancer research and treat-
ment, Dr. Donald Coffey and Dr. Stuart Holden.
The 2017 CHPCA Meeting took place from June 14-17, 2017, in
Carlsbad, California, and was themed “Beyond the Androgen Receptor
II: New Approaches to Understanding and Treating Metastatic
Prostate Cancer.” The meeting was attended by 71 investigators
which included 41 PCF-funded young investigators. The meeting
focused on several of the most promising avenues for improved
biological understanding and treatment of metastatic prostate cancer.
These included: biology and treatment approaches for aggressive
variant castrate resistant prostate cancer (CRPC), epigenetic regulation
of CRPC, the role of DNA repair genemutations in driving prostate and
other cancers, strategic approaches to delivering germline genetics
into actionable clinical practice, development of targeted radionuclides
for imaging and therapy, advances in molecular imaging, and
therapeutic strategies for successful use of immunotherapy in
advanced prostate cancer. In addition to prostate cancer, experts
from several other major fields unrelated to prostate cancer research
attended and contributed fresh research insights and lessons from
breast cancer, ovarian cancer, and astronomy/high-dimension infor-
matics that may be applied to improve studies in prostate cancer.
1.1 | The role of DNA repair in prostate cancer
Studies into mechanisms of DNA repair in prostate cancer have gained
new prominence owing to the recognition that approximately 25% of
metastatic castration resistant prostate cancers carry defects in DNA
repair, particularly in homologous recombination (e.g. BRCA2, ATM,
BRCA1) andmismatch repair (e.g.MLH1,MSH2,MSH6, PMS2).6 Emerging
data suggests prostate cancers with homologous recombination
deficiency (HRD) may be sensitive to poly(ADP) ribosylase inhibitors
(PARPi) and platinum chemotherapy.7,8 These represent potential net
additions to the available treatment options for patients and clinical trials
of PARPi in prostate cancer are currently underway (e.g. NCT02987543,
NCT02952534, and NCT02975934).
Olaparib, rucaparib, and niraparib are now FDA-approved for ovarian
cancer and it isworth considering the parallelswith prostate cancer. BRCA-
mutated ovarian cancers have excellent responses to PARPi and the
response rates appear similar between germline and somatic HRD.
However, observed responses in the absence of BRCA mutations suggest
other factors contribute toPARPi sensitivity.ReportedmechanismsofHRD
include mutations, alterations in gene expression, miRNA expression,
epigenetic modification such as methylation, and/or changes in protein
expression. Efforts are underway to characterize the effects of different
alterations in HRD genes to identify biomarkers that can select patients
most likely to respond to treatment with platinum and PARPi. Alternative
approaches include identification of functional consequences of HRD such
as genomic scarring, analysis of mutational spectra, and/or functional
analyses, such as in cell models. Further efforts to characterize less
commonly mutated genes such as CHEK2, BRIP1, CDK12, and RAD51C
amongothers,aswellas toexploreepigenetic regulationofthesegeneswith
respect to HRD and to sensitivity to platinum and PARPi will be critical.
Unfortunately, while PARPi and platinum-based chemotherapy
can lead to dramatic responses, resistance eventually develops and
there is a need to better understand these mechanisms to develop
strategies aimed at overcoming resistance. Secondary somatic
mutations that restore function of genes initially inactivated have
been described in ovarian cancer9–12 and have now been reported in
prostate cancer.13,14 As molecular profiling methods mature, early
detection of resistance may facilitate additional strategies to predict
and enhance sensitivity and to prevent resistance.
SPOPmutations are commonly observed in primary andmetastatic
prostate cancer,6,15 and preclinical evidence suggests their role in
directing the balance of homologous recombination and non-
homologous end joining DNA repair pathways. Initial data suggests
that SPOPmutations are not sufficient to predict response to PARPi in
CRPC and further work is needed to understand the biological
importance of SPOP mutations and their interactions with key
regulators such as androgen receptor (AR) and DNA repair in prostate
cancer biology.
Ongoing work will identify alternative mechanisms of HRD
orthologs in cancers without known HRD that may sensitize to PARPi
or create synergy with radiation such as Lu177 (a beta-emitter) and
Ac225 (an alpha-emitter). Further understanding of the molecular
interactions between AR regulation and PARP activity, and upstream
interactions such asHOXA9-TWIST interactionwith PARPimay reveal
additional new therapeutic strategies.
1.2 | Advancing germline genetics into clinical
practice
In 2016, a multi-institutional collaboration reported the finding that
over 10% of men with metastatic prostate cancer have germline
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mutations in DNA repair genes such as BRCA2 and other autosomal
dominant high- and medium-penetrance cancer predisposition
genes.16 This finding led to the practice-changing idea that all men
withmetastatic prostate cancer be offered genetic testing for germline
DNA repair gene mutations. With potential implications for treatment
(ie, platinum and PARPi, discussed above) and for family counseling,
the intersection of these discoveries now leads to important new
challenges and opportunities for prostate cancer clinicians on howbest
to identify germline mutation carriers. Again, there are important
parallels and opportunities when considering what has been learned
from the breast and ovarian cancer experience. For example, germline
testing of most/all patients is now common in ovarian cancer, which
improves selection of systemic treatments and clinical trials that target
specific molecular vulnerabilities.
With advances in germline testing for prostate cancer risk genes
also comes the opportunity to refine screening for other cancers (eg,
pancreas, breast, colon, etc), depending on the specific gene and
variant. Cascade germline testing of family members is an important
responsibility that can facilitate risk-adapted cancer screening,
chemoprevention, reproductive counseling, and research opportuni-
ties. Integration of cancer care with genetics services will be
increasingly important in research and clinical care for germline cancer
risk. Areas of uncertainty that require more collaborative investigation
include improved penetrance estimates of individual genes and
variants as well as guidelines for management of men with lower
penetrance risk genes and variants of uncertain significance. A topic
receiving particular attention is the need to diversify populations
studied to interpret genetic variants, particularly given that African
American men are at increased risk of prostate cancer and most
cohorts studied are largely comprised of men of European and/or, in
the case of BRCA1/2 mutations, Ashkenazi Jewish ancestry.
Arguably the greatest potential benefit from germline genetic
testing may lie in the promise of more refined risk-adapted screening
and early detection approaches, which, when combined with appropri-
ate, effective intervention, could avert prostate cancer-specific
mortality. Many additional questions remain to be answered, including
which patients should undergo genetic testing in the localized disease
setting and how management should change. For example, there was
lively discussion, but lack of consensus, on how germline mutations
should influence decisions about active surveillance, and the potential
role for prophylactic prostatectomy in extremely high risk individuals,
for example men with clearly pathogenic germline BRCA2 mutations
with a family history of death from prostate cancer. Given the rapid
evolution in this area, dedicated clinics addressing prostate cancer and
genetic risk have been set up to test new models of care and facilitate
research efforts at the Seattle Cancer Care Alliance/University of
Washington, University of Michigan, Dana-Farber Cancer Institute,
Memorial Sloan Kettering Cancer Center, and Sidney Kimmel Cancer
Center at Thomas Jefferson University, among others. The consensus
from the CHPCA was that further studies are necessary and that close
partnership with patients, along with primary care providers, urologists,
radiation and medical oncologists, and genetics professionals in these
efforts will be critical for success.
1.3 | Epigenetic regulation of prostate cancer
Prostate cancer is in largepart a diseasedrivenby the androgen receptor
(AR), a transcription factor of the steroid nuclear receptor family.17 AR
targeting remains amainstay in the treatment of the disease, both in the
first-line with androgen deprivation therapy (ADT), and at metastatic
castration-resistancewith thepotentARantagonist enzalutamide18 and
the steroidal CYP17A1 inhibitor abiraterone acetate, which inhibits
adrenal production of the natural ligand 5α-dihydrotestosterone
(DHT).19 Resistance inevitably develops to these AR-targeting thera-
pies, implying either loss of sensitivity of AR to ligand-dependent
inhibition, or a switch in the transcriptional regulation of prostate cancer
cells to non-AR-dependent mechanisms.20
The transition from normal prostate to cancer is associated with
extensive reprogramming of AR binding sites within the genome, also
known as the AR cistrome.21 In humans, AR cistromes in prostate
tumors cluster together and are distinctly different from those in
normal prostate tissue.21 AR cistrome reprogramming is associated
with the transcription factors FOXA1 andHOXB13 in primary prostate
tissue,21 as well as with ERG, a member of the ETS family of
transcription factors.22 The AR cistrome is distinctly different between
normal and primary prostate tumor tissue (M. Pomerantz, et al,
unpublished). However, the landscape of the histone acetyl mark
H3K27Ac, an epigeneticmarker of active enhancers, is similar between
normal and primary prostate tissue but differs in models of metastatic
castration-resistant prostate cancer (mCRPC) (M. Pomerantz, et al,
unpublished). Integration of histonemodification landscapes, including
H3K27Ac, with AR and other transcription factor cistromes in models
of CRPC, including in the context of enzalutamide and abiraterone
resistance, will provide broader insight into epigenetic regulation in
advanced prostate cancer.
One such setting is the enzalutamide-resistant prostate cancer
xenograft model LREX, derived from LNCaP-AR xenografts selected
following prolonged exposure to enzalutamide.23 In this model, the
glucocorticoid receptor (GR), another member of the steroid nuclear
receptor family, is overexpressed and assumes key transcriptional
functions of AR, driving tumor growth. GR overexpression in tumors
has been shown to correlate with poor response to enzalutamide,23
and GR activation in the 22Rv1 prostate cancer model has been shown
to promote enzalutamide resistance.24 Importantly, GR overexpres-
sion in LREX is dynamic and induced by AR inhibition with
enzalutamide, with evidence that AR binding to a GR enhancer region
suppresses GR expression (N. Shah, et al, unpublished). GR expression
also has a role in driving tumor survival and poor outcomes in breast
cancer models.25,26 These findings offer an opportunity for GR
targeting in CRPC with epigenetic modulators that affect GR
transcription or with direct GR inhibition.27,28 There are likely to be
additional epigenetic mechanisms of GR activation amenable to
alterative targeting approaches, including dysregulation of glucocorti-
coid metabolism in tumors through enzalutamide-mediated loss of
expression of the metabolic enzyme 11β-HSD2.29
There is clear evidence that epigenetic mechanisms through
reprogramming of epigenetic landscapes and use of alternative
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transcription factors including GR are key in prostate cancer
progression. It will be critical to define the contexts where these
epigenetic driver mechanisms are active in order to exploit them
therapeutically,30 together with targeting of genomic alterations6,7,31
1.4 | Histologic transformation to AR-independent
aggressive variant prostate cancer
Approximately a quarter of CRPC patients acquire an “aggressive
variant prostate cancer” (AVPC) phenotype, which exhibit low to
absent AR levels and expression of neuroendocrine, reprogramming,
and stem-related gene signatures. These tumors are indifferent to AR-
targeted therapy, and evolve from an adenocarcinoma phenotype.32
Recent data suggests that cell reversion to a more plastic state, that is,
lineage plasticity, may be driving the emergence of AVPC, and
understanding this process is critical to designing therapeutic
strategies.
Genomic-sequencing studies and preclinical modeling have
highlighted combinatorial loss of function of tumor suppressor genes,
PTEN, RB1, and TP53, as key genetic events underlying AVPC
progression.32–34 Previously, it was demonstrated that genetically
engineered mouse models of prostate cancer with over-expression of
the large T antigen (TRAMP mice) or co-deletion of TP53 and RB1
develop de novo neuroendocrine prostate cancer (NEPC).35,36
Unfortunately, these models do not accurately represent human
AVPC and its lineage-plastic phenotype. Recently, mice with a
prostate-specific co-deletion of PTEN and RB1 were shown to
develop primary and metastatic prostate cancer.37 These tumors
exhibited co-existence of luminal-like and NEPC-like epithelial cells.
Lineage tracing of tumors suggests that AVPC cells evolve from an
adenocarcinoma cell.37,38 In the PTEN/RB1 double knockout mouse
model, a subset of mice whose tumors acquired spontaneous loss-of-
function TP53 mutations progressed to castration resistance, indicat-
ing that cooperation of TP53, RB1, and PTEN mutations drive
evolution of AVPC.37 Additionally, double knockout of TP53/RB1 in a
human AR dependent prostate cancer cell line (LNCaP-AR) resulted in
a lineage plastic phenotype, with phenotypic and gene expression
changes39 mirroring those described in the PTEN/RB1 double
knockout mouse model. In both models, gene expression patterns
highly overlapped with published human NEPC gene signatures.40
The development of lineage plasticity and castration resistance in
prostate cancers deficient in TP53 and RB1 has been found to occur
through upregulation of SOX2, a stem cell-associated transcription
factor.32,37,39,40 SOX2 expression has been found to be regulated by
RB1, TP3, and BRN2 (Pou3f2) through various mechanisms (P. Mu,
et al. unpublished).41
Amplification of N-MYC (MYCN) has also been implicated in
driving AVPC progression.40,42,43 In a prostate adenocarcinomamouse
model driven by deletion of PTEN, over-expression of N-MYC led to a
phenotype shift to poorly differentiated invasive cancer.42 This data
was in accordance with another study involving combined N-MYC and
myristoylated-AKT1 (myrAKT1) over-expression in human prostate
cell lines and organoids.43 Both studies revealed a gene signature that
included positive enrichment of epithelial-to-mesenchymal transition
and neuronal/stemness/epigenetic gene signatures, and negative
enrichment of AR gene signatures that could distinguish patients with
AVPC.42,43
Increased expression and amplification of AURKA (Aurora Kinase
A), a gene involved in cell cycle, has been observed in human AVPC
samples.40 These findings led to studies in preclinical AVPC models
testing treatment with the allosteric AURKA inhibitor, alisterib,40,42
and the initiation of clinical trials testing the AURKA inhibitor
MLN8237 in patients with mCRPC and NEPC (NCT01799278;
NCT01094288).44 Preclinical data also supports further exploration
into the treatment of AVPC with CD532, a compound that targets the
AURKA:N-MYC interaction and results in degradation of N-MYC.43
Over-expression of the epigenetic reprogramming factor EZH2 is
implicated in human and mouse AVPC.32,37,40,42 EZH2 inhibition has
also been shown to partially reverse AVPC lineage plasticity and re-
sensitize enzalutamide-resistant AVPC models to enzalutamide.37 In
mouse models, EZH2 can dimerize with N-MYC and AURKA, and
EZH2 inhibition resulted in loss of N-MYC expression.42 A study using
newly generated and characterized human AVPC organoids identified
increased expression of EZH2 and its catalytic mark H3K27me3 (L.
Puca et al, unpublished). Screening of AVPC organoid lines with a 129-
chemical compound library in combination with the EZH2 inhibitor
GSK503, identified the kinase inhibitors alisertib and neratinib,
supporting AURKA and overall kinase inhibition as targets of interest
for the treatment of AVPC (L. Puca et al, unpublished). The interaction
between N-MYC and EZH2 may explain how chromatin remodeling
drives lineage switching and a plastic phenotype. This proposed
mechanism is supported by direct interaction between RB1 and EZH2
which directs deposition of H3K27me3.45 This finding raises a critical
question of whether a switch in EZH2 protein interactions drive a
molecular switch through altered distribution of H3K27me3 in the
context of RB1 loss and N-MYC gain of function (L. Ellis and D.
Rickman et al, unpublished).
CEACAM5 has also been suggested as a target in AVPC, and
studies are underway to test CEACAM5-targeted CAR-T cell
immunotherapy (J. Lee et al, unpublished). To date, in vitro data
reveal that CEACAM5 targeting by CAR-T cells show strong on-target
toxicity, and preclinical in vivo evaluation is currently underway (J. Lee
et al, unpublished).
Overall, these studies highlight that interplay between acquired
mutations in tumor suppressor genes and epigenetic and stem cell
regulators underlie the transition from an adenocarcinoma to a
neuroendocrine or AVPC phenotype in addition to gain of castration
resistance. Studies are needed to further clarify the interactions
between these factors and identify optimal strategies for treating or
preventing AVPC.
1.5 | Molecular imaging in prostate cancer
The use of radionuclides (e.g. F18, C11, Zr89) for imaging are
redefining how we view disease states in prostate cancer. The poster-
child of functional imaging in oncology is positron emission
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tomography (PET) with [F18]-fluorodeoxyglucose (FDG). Unfortu-
nately, due to the low glycolytic activity of prostate cancer, FDG PET
plays little to no role in the staging or response assessment for prostate
adenocarcinoma.46 Therefore, standard of care imaging remains
anatomic imaging through CT and monitoring for bone metastasis
via technetium bone scans.47 The limitations of these modalities are
well established, and over the past decade there have been
considerable advancements in the development and clinical testing
of novel compounds to detect prostate cancer. The primary agents
discussed at the CHPCA were C11-choline and PSMA PET.
In the United States, C11-choline has the most evidence to
support its use and was approved by the FDA in 2012 for use at the
Mayo clinic for recurrent prostate cancer, where over 4000 patients
have been scanned to date. For men with recurrent prostate cancer,
C11-choline has a reported sensitivity of 95%, specificity of 86%, and
is most helpful in men with PSA >2 ng/mL.48 Multiple studies from
Mayo clinic have utilized C11-choline to not only document the
patterns of relapse after radical prostatectomy and/or salvage
radiotherapy,49 but to also intervene on these image findings and
optimize treatment for recurrent prostate cancer. Utilizing salvage
lymph node dissections, often including a retroperitoneal lymph node
dissection, the authors have demonstrated the ability to achieve a
biochemical response in 79% of patients, and delay the use of further
therapy, such as hormone therapy by >12 months in those that
recurred.50 However, a poorly defined subset of men (21%) continue
to progress and never achieve an undetectable PSA. Randomized trials
are utilizing C11-choline to guide oligometastasis directed therapy
with a primary endpoint of ADT-free survival, and results from this
study are expected in the near future.51
Prostate-specific membrane antigen (PSMA) is a transmembrane
carboxypeptidase that is expressed in 90-95% of prostate cancer
tumors. There is a direct correlation between expression levels and
tumor aggressiveness.52,53 PSMA imaging to date has largely focused
on documenting the sensitivity and specificity of the radiotracer. The
clinical utility and its ability to impact treatment decisions are less
established and are the focus of multiple ongoing clinical trials
(NCT02981368, NCT02825875). Retrospective comparison studies
have demonstrated PSMA PET may outperform F18-choline, can
impact salvage radiotherapy treatment planning, and may guide use of
stereotactic body radiation therapy (SBRT) for oligometastatic
treatment.54–57 Critical validation studies are needed. Recently,
PSMA PET has been shown to improve initial staging of prostate
cancer compared with MRI and provides complimentary information
when utilized together.58 A key challenge of PSMA imaging relates to
the numerous small molecules that target PSMA (eg, DKFZ-617,
DCFPyL, DCFBC), various radionuclides (F18 and Ga68), and even
minibody and full length antibodies that are being tested. Each of these
in essence functions as its own “drug” and needs to go through
independent testing.
There is little question that these newer molecular imaging
modalities are superior at visualizing the location and burden of
metastatic disease, but the bar must be set higher to gain regulatory
approval and justify the cost of these agents. The consensus from the
CHPCA is that well conducted clinical trials are needed to define the
utility, benefit, and value of molecular imaging in prostate cancer.
These trials are currently ongoing.
1.6 | Radionuclide therapy for metastatic castration
resistant prostate cancer
Radionuclides have been used for over a decade to treat prostate
cancer. Initial radionuclides, such as beta-emitting strontium-89 and
samarium-153, have demonstrated the ability to help palliate painful
bone metastasis with no impact on survival.59,60 In 2013, radium-223
dichloride, an alpha-emitter, gained FDA approval after the positive
phase III ALSYMPCA trial demonstrated not only improvement in pain,
but also significant improvements in overall survival.61 These exciting
results have sparked a resurgence in the interest of utilizing
radionuclide therapy to systemically target metastatic prostate cancer.
Because radium-223 can only target bone metastasis, and
prostate cancer often harbors disease in lymph node or other visceral
sites, new targeting methodologies are being investigated. Given the
specificity of PSMA imaging, PSMA-targeting therapeutic agents
including small urea-based molecules (eg, PSMA-617) and full length
antibodies (eg, J591), conjugated to Lu177 (a beta-emitter) or Ac225
(an alpha-emitter) are being tested. These agents were first tested and
reported clinically in German institutions, wheremultiple retrospective
reports demonstrated examples of exceptional responders to both
agents, with select cases achieving near complete resolution on
molecular imaging and dramatic PSA declines.62–64However, given the
retrospective nature of these studies, concerns for toxicity and
durability of response, and lack of standardized protocol, prospective
trials are now underway around theworld, including Australia, Canada,
and the United States (notably Weill Cornell [NCT03042468] and
UCLA [NCT03042312]). Key questions that remain are how to
optimally dose and fractionate these agents, to determine if a small
molecule, antibody, or combination of both will be optimal to increase
the therapeutic ratio, to determine whether an alpha or beta emitter is
optimal with different PSMA-targeting agents, to assess the response
rates and long-term impact on progression-free survival (PFS) and
overall survival (OS), to quantify the amount and severity of acute and
chronic toxicities, and to determine how to further improve outcomes
through combinatorial treatment approaches.
1.7 | Optimizing checkpoint immunotherapy for the
treatment of prostate cancer
The immune system is designed to recognize foreign or mutated-self
antigens, and as a result, naturally occurring anti-tumor T cell
responses are more frequently observed in tumors with high mutation
and high neoantigen loads, such asmelanoma, lung cancer, and bladder
cancer. These tumor types as well as others with high mutational
burden are sensitive to treatment with checkpoint immunotherapy
(anti-CTLA4, anti-PD1/PD-L1). Prostate cancer, in contrast, is an
“immune desert,” typically having a relatively low number of somatic
mutations and neoantigens, and hence responses to single agent
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checkpoint immunotherapy have been rare. Exceptions are microsat-
ellite instability (MSI)-high or mismatch repair (MMR)-deficient tumors
present in a small subset of mCRPC.6,16,65,66 The anti-PD-1 antibody,
pembrolizumab, recently attained the first-ever cancer-agnostic FDA
approval for patients with unresectable MSI-high or MMR-deficient
solid tumors, including prostate cancer,67 who have progressed on
other therapies and have no other satisfactory treatment options.
Notably, a study in MSI-high colorectal cancer underscored that the
immune status of patients can be a key component of response to
checkpoint immunotherapy.68 Active work is underway to enhance
our understanding of the immune milieu in prostate cancer and to
identify the mechanisms that can ignite the immune system against
prostate cancer.
Two ongoing clinical trials evaluating checkpoint immunotherapy
in prostate cancer have observed improved responses, suggesting
possible therapeutic strategies that may benefit a larger fraction of
men with prostate cancer. The first is investigating the addition of
pembrolizumab after progression on enzalutamide in patients with
mCRPC (NCT02312557).69 An early interim analysis reported signifi-
cant PSA responses in 21% of patients (n = 7/34) (J. Graff et al.,
unpublished).69 An expansion cohort of 30 patients has been added to
this study for a total of 58 patients. A second ongoing trial is testing the
combination of the PARP inhibitor olaparib with the anti-PD-L1
therapy durvalumab in heavily pre-treatedmCPRCpatients unselected
for any genomic alteration (NCT02484404) (F. Karzai et al, unpub-
lished).70 PSA declines have been observed in 68% of the 19 evaluable
patients and partial responses in 4 of 12 evaluable patients thus far.
This study has been expanded to include another 40 patients for a total
of 65. Expansion cohorts in both trials will provide opportunities to
better understand themechanisms of action and patientsmost likely to
benefit. Since the reporting of these two trials, several other studies
testing similar therapeutic strategies are being initiated.
The role for targeting immune checkpoints beyond CTLA-4 and
PD1/PD-L1 is being explored in prostate and other cancers. VISTA is
an immune checkpoint molecule recently found to be upregulated in
prostate cancer.71 A VISTA-targeting therapy is currently being tested
in a phase I clinical trial (NCT02671955), and if shown to be safe, may
lead to trials in prostate cancer.
Alternatively, agonist antibodies activating co-stimulatory mole-
cules expressed on T cells may be an opportunity for rousing anti-
tumor T cells. One potential target is OX40, a T cell costimulatory
molecule that promotes T cell expansion, differentiation, and survival.
Combining OX40-activating antibodies with CTLA4-blockade has
been reported to be synergistic in inducing anti-tumor CD8 T cells,
eliciting tumor regression, and extending survival in prostate mouse
models.72 Anti-OX40/anti-CTLA4 treatment in these mice was found
to elicit a population of CD8 T cells expressing high levels of EOMES, a
marker of central memory T cells. EOMES-high CD8 T cells were
characterized by increased proliferation rates and lower levels of
checkpointmolecules (PD1, LAG3), comparedwith EOMES-lowCD8T
cells, suggesting these cells may be resistant to negative regulatory
effects of checkpoint molecules (W. Redmond, et al, unpublished).
Finally, anti-tumor T cell responses elicited by anti-OX40/anti-CTLA4
treatment may be further enhanced by addition of a vaccine or
radiation therapy,73 (W. Redmond, et al, unpublished).
1.8 | Rationale for combining radiation therapy with
immunotherapy
Radiation therapy canmodulate the immune system through release of
antigens, induction of tumor cell necrosis, activation and expansion of
effector and helper T cells, upregulation of MHC-1, and chemokine
release.74,75 There is data to suggest CD8+ T cells may be required for
tumor killing by radiotherapy.76 Immune stimulation may also
contribute to the therapeutic effects of radium-223. Exposure to
sublethal doses of radium-223 has been shown to increase the
susceptibility of prostate, lung and breast cancer cell lines to T cell
mediated killing.77 In this study, radium-223 treatment was associated
with the induction of CD8+ cytotoxic T cells specific to the tumor
antigens CEA, MUC-1 and brachyury, and was accompanied by
increased expression of MHC-1 and calreticulin, which are proteins
integral to effective antigen presentation.77
Based on these and other observations, many studies have begun
exploring the activity of combining radiation therapy with immunother-
apy for the treatment of prostate cancer. Radiation therapy has been
shown to influence the T cell repertoirewhen given in combinationwith
checkpoint blockade.78 In vivo models found increases in PD-1/PD-L1
expression on immune and tumor cells after radiation and significantly
enhanced efficacy with the addition of anti-PD-L1 to radiation.79 Those
same studies demonstrated decreased levels of immunosuppressive
tumoral myeloid derived suppressor cells (MDSCs), which were
mediated through tumor necrosis factor (TNF).79 A reduction of PD-1
expression on circulating CD8+ and CD4+ T cells has been observed
after a single treatment of radium-223.80 Radium-223 is a rational
partner for immune stimulating agents such as PD-1 pathway blockade
and Sipuleucel-T due to its efficacy, tolerability, and potential for
favorable immunomodulation. Multiple trials are ongoing or planned to
test the addition of radium-223 to immunotherapies such as
pembrolizumab (NCT03093428), atezolizumab (NCT02814669), and
Sipuleucel-T (NCT02463799).
1.9 | Tumor vaccine strategies for prostate cancer
Vaccines that target tumor-associated antigens are being explored in
the clinic as an approach to eliciting anti-tumor immune responses in
tumor types that have a paucity of neoantigens. Approximately 75
vaccine platforms are being explored in prostate cancer clinical trials,
mostly in phase I or II settings. Prostate cancer vaccines that have
made it to phase III testing include Sipuleucel-T, GVAX, Prostvac,
ProstAtak, and DCVAC/PCa. Sipuleucel-T is an autologous cellular
vaccine inwhich antigen presenting cells are immunized ex vivo against
the tumor associated antigen prostatic acid phosphatase (PAP) in the
presence of the immune stimulatory cytokine GM-CSF. Sipuleucel-T
was FDA-approved based on a 4.1 month improvement in median
overall survival over placebo in mCRPC.81 Prostvac is the next furthest
along in development and is currently being tested in the phase III
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PROSPECT trial (NCT01322490). Prostvac is a virus-based vaccine
encoding PSA, along with immune costimulatory molecules LFA-3,
ICAM-1, and B7-1. Results from PROSPECT are anticipated by the end
of 2017. If positive, Prostvac may join Sipuleucel-T as an FDA-
approved vaccine for prostate cancer.
Vaccines alone are unlikely to induce dramatic long-term tumor
regression in prostate cancer, and combinations are being explored
with various other types of immunotherapy including checkpoint
blockade. An ongoing trial at the NCI is testing the combination of
Prostvac with ipilimumab and/or nivolumab (NCT02933255). This trial
includes correlative studies to examine the impact of the different
treatment combinations on the immune compartment in the tumor
microenvironment.
Plasmid-based DNA vaccine strategies have been employed to
induce tumor antigen-specific Th1-based T cell responses and have the
advantage of being highly modifiable to improve antigen targeting.
Plasmid-based DNA vaccines targeting the highly immunogenic
protein SSX-2, a protein involved in stem cell migration and metastatic
potential and which is expressed on approximately 25% of prostate
cancer metastases (pTVG-SSX2), have demonstrated induction of
robust Th1 immune responses.82,83 Combining pTVG-SSX2 with PD-1
blockade resulted in enhanced antitumor effects and immune
responses both in mouse models and in patients enrolled on a phase
I clinical trial, suggesting that combination therapy may be more
effective.84,85 A phase II study is underway combining the pTVG-SSX2
vaccine with PD-1 blockade in metastatic prostate cancer
(NCT02499835).
1.10 | Priming the immune system
The optimal timing of immunotherapy is not well defined; however,
rationale exists for earlier administration during the disease course
when the immune systemmay bemore intact and the disease burden is
low. Neoadjuvant immunotherapy prior to surgery for clinically
localized disease has the potential to downstage tumors, eliminate
micrometastatic disease, and generate durable memory T cell
responses that prevent or delay recurrences. Additionally, the ability
to examine surgical tissue provides the opportunity to investigate
immunomodulatory mechanisms.
GM-CSF has been explored as an immune adjuvant in patients
with prostate cancer with the goals of inducing both innate and
adaptive immunity by activating antigen presenting cells with the
subsequent induction of effector antitumor T cell responses. GM-CSF
may also promote an anti-tumor M1-like phenotype in macrophages,
resulting in direct tumor killing and stimulation of a specific T-cell
mediated anti-tumor response.86–88 In a 13 patient study of GM-CSF
in the metastatic castration-resistant setting, the majority of patients
(92%) exhibited some degree of PSA decline, and one patient had a
sustained and deep PSA response with associated improvement in
bone scans for over 14 months.89
In a neoadjuvant study, the effects of 2-4 weeks of GM-CSF prior
to surgery (n = 18) was explored, using prostatectomy specimens from
untreated subjects as matched controls.90 While GM-CSF was well
tolerated and modulated PSA with the majority experiencing some
degree of PSA decline, only 11% of patients had a >50%PSA decline.90
Induction of a transient peripheral immune responsewas evidenced by
proliferation of cytotoxic and helper T cells and inhibitory T regulatory
cells (Tregs).90 Significant dose-dependent increases in effector and
helper T cell infiltration at the tumor interface and in the tumor were
also observed.90 However, when compared with clinical responses to
PD-1 blockade observed in melanoma,91 the level of immune
infiltration induced by GM-CSF in prostate cancer suggests limited
benefit as a monotherapy, though it may have a role as an adjuvant in
combination strategies. Indeed, the maturing phase III Prostvac study
is poised to address the question of whether adding GM-CSF to
Prostvac enhances efficacy (NCT01322490).
1.11 | Rationale for combining androgen deprivation
therapy with immunotherapy
Evidence suggests that standard therapies such as ADT or radiation
may already be immunomodulatory.74,92 Androgen deprivation may
stimulate lymphocyte and B-cell development, potentiate immune
responses to vaccines, revive thymopoiesis, and abrogate tolerance to
prostate cancer specific antigens.93 Robust T cell infiltration has been
observed in the prostate after androgen ablation, and appears to be
composed more of CD4+ than CD8+ T cells.94 A MycCap model of
prostate cancer demonstrated that castration resulted in an initial T cell
rich pro-inflammatory and suppressive infiltrate, which evolves as the
tumor progresses to castration-resistance (Y. Chen and C. Drake, et al,
submitted).
In mice, castration was found to synergize with depletion of Tregs
with an anti-CTLA-4 antibody, resulting in improved control of tumor
growth (T. Nirschl and C. Drake, et al, submitted). This concept was
tested in a neoadjuvant study ofDegarelix alone or in combinationwith
the GM-CSF vaccine GVAX and the Treg-depleting agent cyclophos-
phamide,95 followed by prostatectomy, in 32 men with high risk
prostate cancer (NCT01696877). In both study arms, immune
stimulation was evidenced by increased CD8 infiltration into tumors
following treatment, however this was rivaled by an equivalent
increase in Treg infiltration (C. Drake, et al, submitted). Nevertheless,
the addition of GVAX + cyclophosphamide to Degaralix resulted in
numerically improved time to PSA recurrence and time to next
treatment (C.Drake, et al, submitted). Overall, these human andmurine
models highlight the complexity of the immune milieu in prostate
cancer and suggest that adding immunomodulatory agents such as
Treg depleting agents to standard hormone therapy may be a fruitful
strategy.
1.12 | Targeting other immune cells in the tumor
microenvironment
Targeting immune-suppressive cells such as myeloid cells and Tregs in
the tumor microenvironment may be promising strategies to enhance
anti-tumor T cell responses and improve clinical outcomes. B cells can
also antagonize anti-tumor T cell activity. In a recent study, mouse
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models of prostate cancer were found to be unresponsive to low dose
oxaliplatin.96 However, anti-tumor T cell responses were observed if B
cells were depleted, suggesting that low-dose oxaliplatin is immuno-
genic and supporting a tumor-promoting role for B cells.96 In these
models, anti-PD-L1 also synergized with low-dose oxaliplatin in
blocking tumor growth.96 These studies support further exploration
into the role of B cells in prostate cancer progression, treatment
resistance, and as a therapeutic target.
Natural Killer (NK) cells are an innate immune cell type with potent
tumor killing potential. NK cells act by targeting cells expressing ligands
to activating NK receptors. These ligands, such as MIC (MHC I Chain
relatedMolecule), are induced by cellular stresses and implicate cells as
being potentially infected or cancerous.97 MIC is highly expressed by
prostate cancer cells as an early response to DNA damage or oxidative
stress.97,98 However, a soluble form of MIC (sMIC) can be produced by
advanced prostate cancer cells, and acts to block the activity ofNKcells,
impair T cell function, and expand immune suppressivemyeloid cells.98–
100 A neutralizing sMIC antibody (mAbB10G5) has been developed and
was demonstrated to reduce primary tumor burden and eliminate
metastases inmousemodels of prostate cancer.101B10G5was found to
synergize with anti-CTLA-4 therapy,102 suggesting that improved anti-
tumor immunity may be achieved by simultaneous activation of T cells
and NK cells. Efforts are underway to complete the preclinical studies
necessary to prepare B10G5 for testing in prostate cancer clinical trials.
2 | CONCLUSION
The 2017 CHPCA Meeting was a highly productive and interactive
experience, with over 400 questions posed across 34 talks. Topics with
the greatest immediate and near-term impact included: (i) how to
screen for and differentially treat men with germline DNA repair gene
mutations; (ii) understanding and optimizing immunotherapy combi-
nations for prostate cancer; and (iii) optimizing PSMA radionuclide
therapy for prostate cancer. PCF will transform these gaps in
knowledge to action through funded research. One immediate
outcome of the meeting was the formation of a PCF-led working
group on DNA repair, which will address questions related to germline
genetics, optimizing methods to identify germline and somatic
mutations, and understanding the biology of various genetic alter-
ations and their association with treatment responses and resistance
to PARPi and platinum chemotherapy.
The theme of the 2018 CHPCA Meeting will be: “Tumor Cell
Heterogeneity and Resistance.”
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